Image

FATIMA MECHTA-GRIGORIOU

Doctor,
Research Director Inserm
Recherche - Paris
Spécialités / domaines
Bioinformatics,
Biology,
Integrative tumor biology, immunology and environment,
Cancer,
Gynécologie,
Heterogeneity,
Immunothérapie,
Metabolomics,
Basic research,
Translational research,
Sénologie
Functions within Institut Curie:
Présentation

Fatima Mechta-Grigoriou, PhD in Science specialized in Cancer Biology. She is Research Director of Exceptional Class at Inserm and Director of the “Stress and Cancer” laboratory at Institut Curie. She is also the deputy director of the research unit U830,  Cancer, Heterogeneity, Instability and Plasticity at Curie Institute and has recently been nominated the Scientific Director of the Cancéropôle Ile de France.

She is an internationally recognized expert investigating the impact of tumor heterogeneity in immunosuppression, metastatic spread and resistance to treatment. Her lab has identified different fibroblast (CAF) populations in several cancers, such as breast, ovarian and lung cancer and revealed that some specific CAF are involved in immunosuppression and resistance to immunotherapies. Her lab also demonstrated the paradoxical effects of Reactive Oxygen Species. Although they are involved in tumor growth and spread, they can also improve sensitivity to chemotherapy.

She received several awards, such as the Rosen Prize 2021, the Grand Prize of the Foundation Del Duca 2018 and the Grand Prize of the Pink Ribbon 2017.

Publications
Assessing personalized responses to anti-PD-1 treatment using patient-derived lung tumor-on-chip
Cell Reports Medicine
Irina Veith, Martin Nurmik, Arianna Mencattini, Isabelle Damei, Christine Lansche, Solenn Brosseau, Giacomo Gropplero, Stéphanie Corgnac, Joanna Filippi, Nicolas Poté, Edouard Guenzi, Anaïs Chassac, Pierre Mordant, Jimena Tosello, Christine Sedlik, Eliane Piaggio, Nicolas Girard, Jacques Camonis, Hamasseh Shirvani, Fathia Mami-Chouaib, Fatima Mechta-Grigoriou, Stéphanie Descroix, Eugenio Martinelli, Gérard Zalcman, Maria Carla Parrini
Residual ANTXR1+ myofibroblasts after chemotherapy inhibit anti-tumor immunity via YAP1 signaling pathway
Nature Communications
Monika Licaj, Rana Mhaidly, Yann Kieffer, Hugo Croizer, Claire Bonneau, Arnaud Meng, Lounes Djerroudi, Kevin Mujangi-Ebeka, Hocine R. Hocine, Brigitte Bourachot, Ilaria Magagna, Renaud Leclere, Lea Guyonnet, Mylene Bohec, Coralie Guérin, Sylvain Baulande, Maud Kamal, Christophe Le Tourneau, Fabrice Lecuru, Véronique Becette, Roman Rouzier, Anne Vincent-Salomon, Geraldine Gentric, Fatima Mechta-Grigoriou
Oxidative phosphorylation is a metabolic vulnerability of endocrine therapy and palbociclib resistant metastatic breast cancers
Nature Communications
Rania El-Botty, Ludivine Morriset, Elodie Montaudon, Zakia Tariq, Anne Schnitzler, Marina Bacci, Nicla Lorito, Laura Sourd, Léa Huguet, Ahmed Dahmani, Pierre Painsec, Heloise Derrien, Sophie Vacher, Julien Masliah-Planchon, Virginie Raynal, Sylvain Baulande, Thibaut Larcher, Anne Vincent-Salomon, Guillaume Dutertre, Paul Cottu, Géraldine Gentric, Fatima Mechta-Grigoriou, Scott Hutton, Keltouma Driouch, Ivan Bièche, Andrea Morandi, Elisabetta Marangoni
A catalog of numerical centrosome defects in epithelial ovarian cancers
EMBO Molecular Medicine
Jean‐Philippe Morretton, Anthony Simon, Aurélie Herbette, Jorge Barbazan, Carlos Pérez‐González, Camille Cosson, Bassirou Mboup, Aurélien Latouche, Tatiana Popova, Yann Kieffer, Anne‐Sophie Macé, Pierre Gestraud, Guillaume Bataillon, Véronique Becette, Didier Meseure, André Nicolas, Odette Mariani, Anne Vincent‐Salomon, Marc‐Henri Stern, Fatima Mechta‐Grigoriou, Sergio Roman Roman, Danijela Matic Vignjevic, Roman Rouzier, Xavier Sastre‐Garau, Oumou Goundiam, Renata Basto